Cervical Cancer Vaccine Gets Priority Review From FDA
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics on February 10, 2006
Merck has announced that its investigational cervical cancer vaccine, Gardasil® (quadrivalent human papillomavirus recombinant vaccine), will be given priority review by the US FDA. A Biologics License Application has been filed, and, with the expedited processing (standard is 10 months), the review may be concluded by June 8, 2006.
Gardasil is designed to protect against four types of human papillomavirus (HPV):
- types 16 and 18, which account for an estimated 70 percent of cervical cancer cases and
- HPV types 6 and 11, which account for an estimated 90 percent of genital wart cases.
According to the National Cervical Cancer Coalition, cervical cancer is the number one cause of cancer-related deaths among women in developing coountries, who account for about 85% of cervical cases worldwide, resulting to approximately 300,000 deaths each year. Additionally, certain low-risk types of HPV cause genital warts, which accounts for approximately one million cases each year in the United States alone.
Merck has also submitted applications for Gardasil to additional regulatory agencies in the European Union, Australia, Mexico, Brazil, Argentina, Taiwan and Singapore.
Gardasil is cited by Forbes to be one of the next drugs to watch, estimating its potential at $500 million to $1 billion in annual sales.

Tags: cervical cancer biotech vaccine review cervical+cancer cancer+vaccine priority+review
Vote for Cervical Cancer Vaccine Gets Priority Review From FDA:
|
Rating: 9.00 out of 2 vote(s) cast.
|
Response from:
Straightfromthedoc
Most cervical cancers in women are linked to the sexually transmitted disease: infection with the genital human papilloma virus (HPV). HPV is also linked to anal cancer in men who have had more sex with men than the general...
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells
